Expanding theranostic radiopharmaceuticals for tumor diagnosis and therapy

Cristina Barca*, Christoph M. Griessinger, Andreas Faust, Dominic Depke, Markus Essler, Albert D. Windhorst, Nick Devoogdt, Kevin M. Brindle, Michael Schäfers, Bastian Zinnhardt, Andreas H. Jacobs*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient diagnosis, therapy, and personalized man-agement. While the definition of theranostics was initially restricted to a single compound allowing visualization and therapy simultaneously, the concept has been widened with the development of theranostic pairs and the combination of nuclear medicine with different types of cancer therapies. Here, we review the clinical applications of different theranostic radiopharmaceuticals in managing different tumor types (differentiated thyroid, neuroendocrine prostate, and breast cancer) that support the combination of innovative oncological therapies such as gene and cell-based therapies with RT.
Original languageEnglish
Article number13
JournalPharmaceuticals
Volume15
Issue number1
DOIs
Publication statusPublished - 1 Jan 2022

Cite this